18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors

The aim of our study was to investigate the efficacy of 18F-Fluciclovine brain PET imaging in recurrent gliomas, and to compare the utility of these images to that of contrast enhanced magnetic resonance imaging (MRI) and to [11C-methyl]-L-methionine (11C-Methionine) PET imaging. We also sought to gain insight into the factors affecting the uptake of 18F-FACBC in both tumors and normal brain, and specifically to evaluate how the uptake in these tissues varied over an extended period of time post injection. Twenty-seven patients with recurrent or progressive primary brain tumor (based on clinical and MRI/CT data) were studied using dynamic 18F-Fluciclovine brain imaging for up to 4 h. Of these, 16 patients also had 11C-Methionine brain scans. Visual findings, semi-quantitative analyses and pharmacokinetic modeling of a subset of the 18F-Fluciclovine images was conducted. The information derived from these analyses were compared to data from 11C-Methionine and to contrast-enhanced MRI. 18F-Fluciclovine was positive for all 27 patients, whereas contrast MRI was indeterminate for three patients. Tumor 18F-Fluciclovine SUVmax ranged from 1.5 to 10.5 (average: 4.5 ± 2.3), while 11C-Methionine’s tumor SUVmax ranged from 2.2 to 10.2 (average: 5.0 ± 2.2). Image contrast was higher with 18F-Fluciclovine compared to 11C-Methionine (p < 0.0001). This was due to 18F-Fluciclovine’s lower background in normal brain tissue (0.5 ± 0.2 compared to 1.3 ± 0.4 for 11C-Methionine). 18F-Fluciclovine uptake in both normal brain and tumors was well described by a simple one-compartment (three-parameter: Vb,k1,k2) model. Normal brain was found to approach transient equilibrium with a half-time that varied greatly, ranging from 1.5 to 8.3 h (mean 2.7 ± 2.3 h), and achieving a consistent final distribution volume averaging 1.4 ± 0.2 ml/cc. Tumors equilibrated more rapidly (t1/2ranging from 4 to 148 min, average 57 ± 51 min), with an average distribution volume of 3.2 ± 1.1 ml/cc. A qualitative comparison showed that the rate of normal brain uptake of 11C-Methionine was much faster than that of 18F-Fluciclovine. Tumor uptake of 18F-Fluciclovine correlated well with the established brain tumor imaging agent 11C-Methionine but provided significantly higher image contrast. 18F-Fluciclovine may be particularly useful when the contrast MRI is non-diagnostic. Based on the data gathered, we were unable to determine whether Fluciclovine uptake was due solely to recurrent tumor or if inflammation or other processes also contributed.

[1]  D. Schuster,et al.  Comparative evaluation of transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid and l-[methyl-11C]methionine in human glioma cell lines , 2013, Brain Research.

[2]  A. Okumura,et al.  Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  D. Schuster,et al.  Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases , 2017, International journal of molecular sciences.

[4]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Schuster,et al.  Differences in Transport Mechanisms of trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with l-[Methyl-11C]Methionine and 2-Deoxy-2-[18F]Fluoro-d-Glucose , 2014, Molecular Imaging and Biology.

[6]  J. Votaw,et al.  Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[8]  L. R. Dice Measures of the Amount of Ecologic Association Between Species , 1945 .

[9]  B. Fuchs,et al.  Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? , 2005, Seminars in cancer biology.

[10]  T. Poeppel,et al.  68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin , 2016, The Journal of Nuclear Medicine.

[11]  H. Matsuda,et al.  Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial , 2017, Asia Oceania journal of nuclear medicine & biology.

[12]  N. Tsuyuguchi,et al.  Diagnosis of Brain Tumors Using Amino Acid Transport PET Imaging with 18F-fluciclovine: A Comparative Study with L-methyl-11C-methionine PET Imaging , 2017, Asia Oceania journal of nuclear medicine & biology.

[13]  T. Sørensen,et al.  A method of establishing group of equal amplitude in plant sociobiology based on similarity of species content and its application to analyses of the vegetation on Danish commons , 1948 .

[14]  K. Van Laere,et al.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  D. Schuster,et al.  Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. , 2013, Nuclear medicine and biology.

[16]  S. Aoki,et al.  Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors , 2016, Annals of Nuclear Medicine.

[17]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[18]  Ian Law,et al.  The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy , 2016, NeuroImage: Clinical.

[19]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  Ephraim E. Parent,et al.  [18F]Fluciclovine PET discrimination between high- and low-grade gliomas , 2018, EJNMMI Research.

[21]  Wolfgang A. Weber,et al.  O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.

[22]  T. Nihashi,et al.  Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis , 2013, American Journal of Neuroradiology.

[23]  M. Goodman,et al.  Synthesis of [F‐18]‐1‐amino‐3‐fluorocyclobutane‐1‐carboxylic acid (FACBC): a PET tracer for tumor delineation , 1999 .

[24]  N. Shikano,et al.  Putative Transport Mechanism and Intracellular Fate of Trans-1-Amino-3-18F-Fluorocyclobutanecarboxylic Acid in Human Prostate Cancer , 2011, The Journal of Nuclear Medicine.

[25]  N. Galldiks,et al.  Amino Acid PET – An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence? , 2016, Front. Neurol..